IMUNON INC (IMNN)
US15117N6022 - Common Stock
IMUNON INC
NASDAQ:IMNN (12/20/2024, 4:33:45 PM)
After market: 0.8201 -0.01 (-1.19%)0.83
-0.02 (-2.83%)
Company Profile
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 33 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The firm is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Company Info
IMUNON INC
997 Lenox Dr Ste 100
Lawrenceville NEW JERSEY
P: 16098969100
Employees: 33
Website: https://imunon.com/
IMNN News
a day ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Stay updated with the stocks that are on the move in today's after-hours session.
a day ago - Imunon, Inc.IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian CancerCompany aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components...
10 days ago - Imunon, Inc.IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of...
25 days ago - Imunon, Inc.IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian CancerFDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and...
a month ago - Imunon, Inc.IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual MeetingIMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival...
a month ago - Imunon, Inc.IMUNON Reports Third Quarter 2024 Financial Results and Provides Business UpdatesConference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in...
IMNN Twits
Here you can normally see the latest stock twits on IMNN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
